The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1422206
This article is part of the Research Topic Tertiary lymphoid structures (TLS) in the tumor immune microenvironment View all 13 articles
Exploring the Impact of Tertiary Lymphoid Structures Maturity in NSCLC: Insights from TLS Scoring
Provisionally accepted- 1 AstraZeneca (United Kingdom), London, England, United Kingdom
- 2 AstraZeneca (Germany), Wedel, Schleswig-Holstein, Germany
- 3 AstraZeneca, Waltham, United States
- 4 AstraZeneca (United States), Wilmington, Delaware, United States
- 5 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, Île-de-France, France
- 6 Université Sorbonne Paris Cité, Paris, France
- 7 Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Paris, France
- 8 Department of Otolaryngology, Head and Neck Surgery, VU Medical Center, Amsterdam, Netherlands, Netherlands
- 9 Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands
- 10 Amsterdam Institute for Infection and Immunity, VU Medical Center, Amsterdam, Netherlands
- 11 Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and multiple features such as TLS size, composition, and maturation status, when assessing their functional impact. With the aim of gaining insights into TLS biology and evaluating the prognostic impact of TLS maturity in Non-Small Cell Lung Carcinoma (NSCLC), we developed a multiplex immunofluorescent (mIF) panel including T cell (CD3, CD8), B cell (CD20), Follicular Dendritic cell (FDC) (CD21, CD23) and mature dendritic cell (DC-LAMP) markers. We deployed this panel across a cohort of primary tumor resections from NSCLC patients (N=406) and established a mIF image analysis workstream to specifically detect TLS structures and evaluate the density of each cell phenotype. We assessed the prognostic significance of TLS size, number, and composition, to develop a TLS scoring system representative of TLS biology within a tumor. TLS relative area, (total TLS area divided by the total tumor area), was the most prognostic TLS feature (C-index: 0.54, p = 0.04). CD21 positivity was a marker driving the favourable prognostic impact, where CD21+ CD23- B cells (C-index: 0.57, p = 0.04) and CD21+ CD23- FDC (C-index: 0.58, p = 0.01) were the only prognostic cell phenotypes in TLS. Combining the three most robust prognostic TLS features: TLS relative area, the density of B cells, and FDC CD21+ CD23- we generated a TLS scoring system that demonstrated strong prognostic value in NSCLC when considering the effect of age, sex, histology, and smoking status. This TLS Score also demonstrated significant association with Immunoscore, EGFR mutational status and gene expression-based B-cell and TLS signature scores. It was not correlated with PD-L1 status in tumor cells or immune cells.
Keywords: NSCLC, tertiary lymphoid structures, Tissue scoring, tumor immunity, Multiplex immunofluorescence
Received: 23 Apr 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Berthe, Poudel, Segerer, Jennings, Ng, Surace, Andoni, Testori, Saraiya, Vuko, Hessel, Heininen- Brown, Blando, Jones, Willis, Galon, Van De Ven, De Gruijl and Angell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Helen K. Angell, AstraZeneca (United Kingdom), London, England, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.